We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.37B
AUM Growth
+$301M
Cap. Flow
+$225M
Cap. Flow %
16.4%
Top 10 Hldgs %
27.24%
Holding
130
New
25
Increased
53
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$31.4M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$15.5M
3
COLL icon
Collegium Pharmaceutical
COLL
+$13M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.6M
5
ACHC icon
Acadia Healthcare
ACHC
+$10.7M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$22.5M
2
SRCL
Stericycle Inc
SRCL
+$10.3M
3
LH icon
Labcorp
LH
+$9.46M
4
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$7.97M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 76.77%
2 Financials 1.46%
3 Technology 0.96%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
126
DELISTED
Aerie Pharmaceuticals
AERI
– –
-146,000
Closed -$4.58M
TRIV
127
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
– –
-198,000
Closed -$2.08M
ACT.PRA
128
DELISTED
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
– –
-5,000
Closed -$5.15M
PCYC
129
DELISTED
PHARMACYCLICS INC
PCYC
– –
-88,000
Closed -$22.5M
ETRM
130
DELISTED
EnteroMedics Inc.
ETRM
– –
-773
Closed -$743K
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rock Springs Capital Management held 130 positions worth $1.37B, up 28% from $1.07B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $225M of net new capital in Q2 2015, opening 25 new positions and adding to 53 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $6.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2015 buy was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.
  • Rock Springs Capital Management added most to Spark Therapeutics, Inc. Common Stock in Q2 2015, an estimated $31.4M increase.
  • Rock Springs Capital Management's biggest Q2 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $6.9M.
  • Rock Springs Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $22.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.37B portfolio in Q2 2015.
  • Rock Springs Capital Management opened 25 new positions and closed 13 in Q2 2015.
  • Rock Springs Capital Management's portfolio value rose 28% quarter-over-quarter to $1.37B.

Based on Rock Springs Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.